Democratic People's Republic of Korea

Effect of enhanced investment scenario*					
	Baseline 2011	Constant coverage scenario 2035	Enhanced investment scenario with R&D 2035	Events averted by enhanced investment in 2035	
Reproductive, maternal, newborn, and child health				**A**	**B**
Births	372	372	372	0	0
Total fertility rate	2.0	2.0	2.0	*	*
Maternal deaths	<1	<1	<1	<1	<1
Stillbirths	4	4	2	2	1
Total under-5 child deaths	14	14	5	9	5
Under-5 mortality rate	38	39	15	*	*
Maternal mortality ratio	70	70	30	*	*
Tuberculosis					
New cases	84	58	17	41	41
Deaths	4	3	1	2	2
HIV/AIDS					
New infections	0	0	0	0	0
Deaths in people aged 5 years and over	0	0	0	0	0
Total deaths	**23**	**22**	**8**	**13**	**8**

***Effect of enhanced investment scenario**

For births, stillbirths, cases, deaths, and infections, the annual rate is in thousands. The results have been rounded. R&D=research and development. *Events averted in 2035 is defined as the difference between the constant coverage scenario in 2035 and the enhanced investment scenario with R&D in 2035 (ie, enhanced investment including scale up of new tools developed by R&D). Column A includes stillbirths and child deaths averted because a pregnancy was averted-ie, column A includes potential deaths among individuals who never existed. Column B excludes these deaths-ie, column B shows only deaths associated with pregnancies that did actually occur. The total fertility rate is expressed as the number of births expected per woman at the then-prevailing age-specific mortality and fertility rates. The under-5 mortality rate is defined as the probability of dying between birth and 5 years of age at the age-specific mortality rates of the indicated year (denoted by demographers as 5q0). The maternal mortality ratio is the number of women who die during pregnancy and childbirth, per 100,000 livebirths.

Incremental costs of enhanced investment scenario^					
Us $ million	Incremental costs 2015	Incremental costs 2025	Incremental costs 2035	Incremental costs 2016-2025	Incremental costs 2026-2035
Programmatic investment (scaling up current interventions)					
Family planning	0	0	1	3	4
Maternal and neonatal health	3	28	47	146	401
Immunization	11	47	58	276	541
Treatment of childhood illness	1	6	6	41	62
Malaria	24	41	58	324	511
Tuberculosis	36	13	6	208	91
HIV/AIDS	0	1	2	6	16
Subtotal	77	137	178	1,003	1,626
Health system strengthening					
Incremental investment	490	359	383	3,805	3,730
All new tools and interventions	465	407	460	3,942	4,391
Total investment	**1,032**	**903**	**1,021**	**8,751**	**9,747**
Ratios					
Cost per death averted ($)	274,825	72,524	80,287	92,981	74,468
Population (m)	26	28	29	270	284
Incremental cost per capita ($)	39.40	32.66	35.39	32.44	34.36

^Incremental costs of enhanced investment scenario

Population is total, not incremental. Treatment of childhood illness excludes malaria costs, TB costs exclude ART for HIV+ TB patients. Scale up of new products assumed to increase reduction in annual mortality and infection rates by incremental 2%.


Maternal Mortality Ratio
Maternal mortaly ratio (deaths per 100,000 livebirths)
90
80
70
60
50
40
30
20
10
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target


Under-5 Mortality Rate
Under-5 mortality rate (deaths per 1,000 livebirths)
45
40
35
30
25
20
15
10
5
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target


AIDS Death Rate
AIDS death rate (deaths per 100,000 persons)
9
8
7
6
5
4
3
2
1
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target


TB Death Rate
TB death rate (deaths per 100,000 persons)
18
16
14
12
10
8
6
4
2
0
2011
2015
2020
2025
2030
2035
Year
Constant Coverage
Enhanced Investment Scenario
Enhanced Investment Scenario with R&D
Convergence Target